Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)

HNX:DP3 Balance Sheet

Financials in millions VND. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6,629	4,476	13,706	5,375	21,106	24,727
Short-Term Investments	441,017	470,988	327,987	301,000	185,378	137,000
Cash & Short-Term Investments	447,646	475,464	341,693	306,375	206,484	161,727
Cash Growth	10.47%	39.15%	11.53%	48.38%	27.67%	0.50%
Accounts Receivable	55,848	43,305	34,817	17,061	26,898	20,857
Other Receivables	10,174	7,316	4,539	5,722	1,758	318.51
Receivables	66,022	50,622	39,356	22,784	28,656	21,175
Inventory	82,828	56,667	43,925	52,332	69,835	67,159
Prepaid Expenses	498.84	306.77	222.42	247.03	49.57	334.52
Other Current Assets	3,405	4,489	8,129	2,014	5,161	5,050
Total Current Assets	600,400	587,549	433,326	383,752	310,186	255,446
Property, Plant & Equipment	112,747	114,288	119,745	131,247	154,414	145,838
Other Intangible Assets	20,081	20,121	20,201	20,281	6,514	6,594
Other Long-Term Assets	33,801	34,128	34,504	35,346	36,755	37,626
Total Assets	767,029	756,086	607,777	570,626	507,868	445,504

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Accounts Payable	15,546	20,212	7,642	15,695	18,474	19,499
Accrued Expenses	105,910	65,132	63,340	59,112	50,742	44,398
Short-Term Debt	21,857	34,273	-	6,800	5,230	3,528
Current Income Taxes Payable	15,599	18,610	13,243	14,240	10,594	8,084
Other Current Liabilities	9,806	7,405	4,671	5,333	5,378	3,746
Total Current Liabilities	168,719	145,632	88,896	101,179	90,418	79,254
Long-Term Debt	-	-	-	975	-	-
Total Liabilities	168,719	145,632	88,896	102,154	90,418	79,254

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Common Stock	214,999	214,999	214,999	214,999	86,000	86,000
Additional Paid-In Capital	-	-	-	-	97,659	97,659
Retained Earnings	383,311	395,455	303,881	253,473	233,791	182,591
Shareholders' Equity	598,310	610,454	518,881	468,472	417,450	366,250
Total Liabilities & Equity	767,029	756,086	607,777	570,626	507,868	445,504

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Total Debt	21,857	34,273	-	7,775	5,230	3,528
Net Cash (Debt)	425,789	441,191	341,693	298,600	201,254	158,199
Net Cash Growth	10.48%	29.12%	14.43%	48.37%	27.21%	1.71%
Net Cash Per Share	19804.19	20520.58	15892.74	13888.41	8892.41	7358.34
Filing Date Shares Outstanding	21.5	21.5	21.5	21.5	21.5	21.5
Total Common Shares Outstanding	21.5	21.5	21.5	21.5	21.5	21.5
Working Capital	431,681	441,917	344,430	282,572	219,768	176,192
Book Value Per Share	27828.47	28393.31	24134.06	21789.47	19416.28	17034.87
Tangible Book Value	578,229	590,333	498,679	448,191	410,936	359,656
Tangible Book Value Per Share	26894.45	27457.42	23194.45	20846.14	19113.30	16728.17
Buildings	128,321	128,321	126,884	126,668	-	-
Machinery	113,315	109,865	109,367	109,269	-	-
Construction In Progress	4,594	3,864	120	401.11	14,390	5,436

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 9, 2026

Data Sources Report a data error